The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What is the clinical value and potential of momelotinib for anemic patients with myelofibrosis?

Sep 9, 2020
Share:

During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to Abdulraheem Yacoub, University of Kansas Medical Center, Kansas City, US, about anemia in myelofibrosis (MF). We asked, What is the clinical value and potential of momelotinib for anemic patients with MF, and how does it compare to other JAK inhibitors (JAKi)?

What is the clinical value and potential of momelotinib for anemic patients with myelofibrosis?

Anemia is a hallmark of MF and can also be a prognostic factor, with severe anemia indicating severe disease and therefore a poorer outcome. Anemia is responsible for high symptom burden in patients with MF. Many of the current treatments for MF can increase the severity of anemia, and therefore this indicates a clear unmet need for novel therapies.

Share: